Loading clinical trials...
Loading clinical trials...
A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod)
Conditions
Interventions
Fingolimod
Natalizumab
Locations
1
Germany
Universitaetsklinikum Muenster, Department of Neurology
Münster, Germany
Start Date
March 1, 2014
Primary Completion Date
April 1, 2016
Completion Date
April 1, 2016
Last Updated
December 25, 2014
NCT04047628
NCT04602390
NCT05978531
NCT04225312
NCT03536559
NCT05446285
Lead Sponsor
University Hospital Muenster
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions